News

Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. Warner Chilcott has previously announced the filing of

Zoll Medical is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation technologies, ventilation, and fluid resuscitation, Zoll provides a

Novartis said that Coartem dispersible contains the same amounts of artemether and lumefantrine as Coartem, the leading artemisinin-based combination therapy (ACT) in Africa, and is the first dispersible

The trial is a proof-of-concept, open-label study with pediatric subjects randomized according to weight group and titrated to receive one of four doses over a six-week treatment period.

The results showed that Embeda provided continued pain relief for up to 12 months in opioid-tolerant patients with chronic, moderate to severe, non-malignant pain. Findings also showed that

The company has posted net sales of $10.08 billion for the fourth quarter of 2008, an increase of 1%, compared to $9.93 billion reported for the fourth quarter

The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick Advance test, and represents a six-month increase in

Together with the hepatitis C virus (HCV) Respond-2 study, a pivotal Phase III study in patients who failed prior treatment that completed enrollment in November 2008, the company

In addition, there will be the elimination of approximately 410 CSO sales representative positions. In total, Sepracor sales positions will be reduced to approximately 1,325. These reductions, together